Date post: | 22-Aug-2019 |
Category: |
Documents |
Upload: | vuongthien |
View: | 213 times |
Download: | 0 times |
LEBANESE AMERICAN UNIVERSITY
Targeting the MAP Kinase pathway in Human Acute Myeloid
Leukemia Cells using a recombinant Anthrax Lethal Toxin
By
Elias Kassab
This work has been published: Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic
and dependent on extracellular signal-regulated kinase 1/2 activity. Kassab E, Darwish M, Timsah Z, Liu S, Leppla SH, Frankel AE, Abi-Habib RJ.
Transl Oncol. 2013 Feb;6(1):25-32. Epub 2013 Feb
A thesis
Submitted in partial fulfillment of the requirements
for the degree of Master of Science in Molecular Biology
School of Arts and Sciences
May 2013
ii
iii
iv
v
vi
vii
Acknowledgment
I would like to express my deepest appreciation to all those who provided me the
patience and strength to complete this thesis. A special gratitude I give to my parents and
family whose encouragement has made this possible.
Furthermore I would also like to acknowledge with sincere gratitude the crucial role
of my supervisor, mentor and close friend Dr. Ralph Abi-Habib to whom I owe most of
what I achieved in my educational life and career.
viii
“To Pierre & Carmen Kassab I dedicate this thesis”
ix
Targeting the MAP Kinase pathway in Human Acute Myeloid
Leukemia Cells using a recombinant Anthrax Lethal Toxin
Elias Kassab
Abstract
In this study, we attempt to target the mitogen-activated protein kinase (MAPK) pathway
in acute myeloid leukemia (AML) cells using a recombinant anthrax lethal toxin (LeTx).
Around 15,000 new case of Acute Myeloid Leukemia are diagnosed each year with a
fatality rate of 65%. The poor prognosis rate is due to the high proliferative and quick
progressive characteristics of AML. However, most AML patients eventually relapse due
to persistence of chemotherapy-resistant blasts in the bone marrow hence the need for
alternative approaches employing novel, more selective mechanisms for targeting AML
blasts. One such approach consists of targeting the mitogen-activated protein (MAP)
kinase (MAPK) pathway in AML cells. LeTx consists of protective antigen (PrAg) and
lethal factor (LF). PrAg binds cells, is cleaved by furin, oligomerizes, binds three to four
molecules of LF, and undergoes endocytosis, releasing LF into the cytosol. LF cleaves
MAPK kinases, inhibiting the MAPK pathway. The MAKP pathway is a conserved
pathway between eukaryotes. Through a wide range of extracellular signals, the MAPK
pathway regulates growth, proliferation, differentiation and death. Its constitutive
activation, particularly the Ras/Raf/MEK1/2/ERK1/2 cascade promotes proliferation and
survival of most human cancer cells.
x
We tested potency of LeTx on a panel of 11 human AML cell lines. Seven cell lines
showed cytotoxic responses to LeTx. Cytotoxicity of LeTx was mimicked by the specific
mitogen-activated protein/extracellular signal–regulated kinase kinase 1/2 (MEK1/2)
inhibitor U0126, indicating that LeTx-induced cell death is mediated through the
MEK1/2–extracellular signal–regulated kinase (ERK1/2) branch of the MAPK pathway.
The four LeTx-resistant cell lines were sensitive to the phosphatidylinositol 3-kinase
inhibitor LY294002. Flow cytometry analysis of MAPK pathway activation revealed
presence of phospho-ERK1/2 only in LeTx-sensitive cells. In this study, we have shown
that a majority of AML cell lines are sensitive to the LF-mediated inhibition of the
MAPK pathway. Furthermore, we have demonstrated that LeTx-induced cytotoxicity in
AML cells is non-apoptotic and dependent on phospho-ERK1/2 levels.
Keywords: Mitogen-Activated Protein Kinase, Acute Myeloid Leukemia, Anthrax
Lethal Toxin, ERK1/2, MEK1/2, Cytotoxicity, Flow Cytometry, Western Blot.
xi
TABLE OF CONTENTS List of Tables…………………………………………………………………………...7
List of Figures………………………………………………………………………….8
Glossary……………………………………………………………………………….9-10
Chapter Page
I- Introduction
1.1. Overview of Acute Myeloid Leukemia 10
1.2. Targeting the MAPK pathway 12
1.3.The MAPK pathway 13
1.4. Anthrax Lethal Toxin (Letx) 15
1.5.Previous work 17
II- Materials and methods
2.1 Expression and purification of PrAg, LF and FP59 18
2.2 Cells and cell lines 19
2.3 Proliferation inhibition assay (cytotoxicity) 20
2.4 Cell cycle analysis 21
2.5 Inhibition Assays 21
2.6 Protein Extraction and Western Blotting 22
2.7 Intracellular Staining and Flow Cytometry Analysis 23
2.8 Analysis of Cell Cytotoxicity 24
III- Results
3.1 Cytotoxicity of Anthrax Lethal Toxin 25
3.2 Cell cycle effect of Anthrax Lethal Toxin 30
3.3 Inhibition of PI3 Kinase 35
3.4 Analysis of MAPK Activation 38
3.5 Analysis of Cell Death 42
IV- Discussion 45
V- Bibliography 50
xii
LIST OF TABLES
Table Table Title Page
Table 1. Sensitivity of human AML cell lines to LeTx (PrAg/LF), 26
U0126 and the protein synthesis inhibitor PrAg/FP59.
Table 2. Sensitivity of human AML cell lines to LeTx (PrAg/LF) 41
and activation level of the MAPK pathway illustrated by
the ratio of Phospho to total ERK1/2 levels.
xiii
LIST OF FIGURES
Figure Figure Title Page
Figure 1: Schematic overview of the Mitogen-Activated Protein Kinase Pathway. 13
Figure 2: Mechanism of action of Anthrax toxin. 16
Figure 3: Non-Linear regression curves of LeTx (PrAg/LF)
and PrAg/FP59 on human AML cell lines. 29
Figure 4: Cell cycle analysis of AML cell lines following treatment with LeTx 34
Figure 5: Sensitivity of LeTx-resistant AML cell lines to LY294002 alone
and in combination with LeTx 38
Figure 6: Single cell, intracellular staining of Phospho-ERK1/2 in 4 AML cell
lines using flow cytometry. 39
Figure 7: Analysis of the mechanism of LeTx-mediated cytotoxicity in TF1-vRaf
cells using annexin V/PI and active caspase staining. 44
xiv
GLOSSARY
AML Acute myeloid leukemia
LeTx Anthrax lethal toxin
PrAg Protective antigen
LF Lethal Factor
ANTXRs Anthrax toxin receptors
TEM-8 Tumor endothelium marker 8
CMG-2 Capillary Morphogenesis Gene 2
MAPK Mitogen-activated protein kinase
JNK c-Jun NH2-terminal kinase
Gab1 Grb2-associated binder 1
PH Plekstrin Homology
TNF-α Tumor necrosis factor- α
MEK Mitogen-activated protein kinase kinase
ERK Extracellular signal-regulated kinase
SEK1 SAPK-stress-activated protein kinase-/c-Jun NH2-terminal kinase /Erk
kinase
MLK Mixed-lineage kinase
ASK1 Apoptosis signal-regulating kinase 1
xv
PAI-1 Plasminogen activator inhibitor- 1
MMP Metalloprotease
FP59 Pseudomonas aeruginosa exotoxin A
EF-2 Elongation factor 2
Ras Rat-adeno-sarcoma
RTK Receptor tyrosine kinase
GRB2 Growth factor receptor-bound protein 2
SOS Son of Sevenless
GEF Guanine nucleotide exchange factor
PI3K Phosphatidylinositol 3-kinase
PI(4,5)P2 Phosphatidylinositol 4,5-bisphosphate
PDK1 3-phosphoinositide-dependent protein kinase-1
1
CHAPTER ONE
INTRODUCTION
1.1 Overview of Acute Myeloid Leukemia
According to The American Cancer Society, the 2013 estimates for Leukemia of all kinds
in the United States are approximately 48,610 newly diagnosed cases with approximately
23,720 deaths. Acute Myeloid Leukemia (AML) is one of the most common leukemias in
adults with an estimated 14,590 newly diagnosed cases in 2013, mainly in adults, and an
estimated 10,370 deaths. AML is usually common in older individuals and rarely
diagnosed in people below the age of 40, with the mean age of 67 for patients diagnosed
with AML. The lifetime risk of acquiring AML in the average man is approximately 1 in
232 while in the average woman is 1 in 278, hence making AML slightly more frequent
in men than women (American Cancer Society, 2013). AML is highly proliferative and
its quick progression with the lack of effective treatment has a very poor prognosis.
According to the World Health Organization (WHO), AML is classified into four
different subtypes according to clinical and genetic factors. On the other hand, the
French-American-British (FAB) organization classifies AML into eight different
subtypes, M0 to M7, depending on the cell type and degree of maturity. Over the past
three decades, new therapeutic schemes have been developed that were successful in
increasing complete remission in patients following combination induction and
consolidation chemotherapy (American Cancer Society, 2013). The widely used
chemotherapeutic agents are “Cytarabine”, “Doxorubicin” and “Mitoxantrone”.
2
Radiotherapy is an option for AML patients followed by bone marrow transplant from an
appropriate donor. However, most patients eventually relapse due to persistence of
chemotherapy-resistant blasts in the bone marrow (Bennett JM, 2002). Relapse rates
differ depending on the patient and the AML subtype, the rates range from 33% to 78%
with an average of 50%. Such patients with refractory and relapsed AML, unfortunately,
have no effective therapeutic options, with the disease remaining incurable in most
(Bennett JM, 2002). Hence, alternative approaches employing novel, more selective
mechanisms for targeting AML blasts are being sought. One such approach consists of
targeting the mitogen-activated protein (MAP) kinase (MAPK) pathway in AML cells
using a recombinant anthrax lethal toxin (LeTx) (Davies SP, 1999) (Koo HM, 2002)
(Abi-Habib RJ U. J., 2005).
3
1.2 Targeting the MAPK pathway
The potential for targeting the MAPK pathway in AML has not been fully investigated
yet. A number of studies have been carried out in the past years investigating the role
played by the MAPK pathway in AML cell lines and in blasts from AML patient with
very few studies attempting to target the MAPK pathway in AML. In one study, Non-
steroidal anti-inflammatory drugs (NSAIDs), were analyzed and proved to induce
apoptosis in both AML cell lines and patient samples through the constitutive activation
of c-Jun N-terminal kinases (JNKs), which are part of the MAPK family (Singh R, 2011).
Another study conducted showed the important role of the MAPK pathway in blocking
the oxidative stress induced senescence in AML (Xiao Y, 2012). Nargenicin, a polyketide
antibiotic, was demonstrated as a possible treatment of neoplastic diseases, through its
role in enhancing leukemia cell differentiation by targeting the
PKCbeta1/MAPK pathways (Kim SH, 2009).
4
1.3 The MAPK pathway
The MAPK pathway is a highly conserved signaling pathway among all eukaryotes; it
plays a key role in the transduction of a wide range of extracellular signals. Such signals
have a critical role in regulating growth, proliferation, differentiation and apoptosis in
eukaryotic cells. Constitutive activation of the MAPK pathway leads to cell proliferation
and survival in most human cancers (Abi-Habib RJ U. J., 2005) (Wellbrock C, 2004).
Figure 1. Schematic overview of the Mitogen-Activated Protein Kinase Pathway (AS
Dhillon, 2007).
As depicted in figure 1, a three tier kinase module makes up the MAPK pathway where
the phosphorylation of one (MAPKKK), is activated and in turn phosphorylates its
downstream processor, therefore activating the pathway. Specific abnormalities and
5
deviations in the MAPK signaling pathway enhance the development and progression of
cancer cells through the acquirement of capabilities such as: liberty of proliferation
signals, apoptotic evasion, lack of sensitivity to anti-growth signals, infinite replication
potential, angiogenis, invasion, metastasis, drug resistance and resistance to oncogene
induced senescence. As seen in figure 1, activated Raf will, through phosphorylation,
activate MEK1 and MEK2. There exists three different isoforrms that differ in their
abilities to activate both MEK1/2. Raf-1 is one of the Raf isoforms that efficiently
activates both MEK1/2 equally. Once ERK1/2 is activated by MEK, it phosphorylates
several cytoplasmic and nuclear targets such as kinases, phosphatases, cytoskeletal
proteins and transcription factors. These ERK signals will in-turn regulate the processes
related to cell development and progression discussed earlier. Mutations leading to the
constitutive activation of the Ras-Raf-MEK1/2-ERK1/2 pathway are a hallmark of
several tumors such as melanoma and are found in a variety of cancers, including AML,
thus constituting an attractive target for novel AML therapies (Lee JT Jr, 2002) (Hilger
RA, 2002) (Wu, 2004) (Milella M K. S., 2001) (AS Dhillon, 2007).
6
1.4 Anthrax Lethal Toxin
LeTx is a binary toxin produced by the gram positive bacterium Bacillus anthracis and
consisting of two separate proteins: the cell binding and internalization moiety protective
antigen (PrAg) and the catalytic moiety lethal factor (LF) (Bradley KA M. J., 2001)
(Scobie HM, 2003). PrAg binds to cells through its ubiquitously expressed cell surface
receptors tumor endothelial marker-8 (TEM-8) and capillary morphogenesis gene-2
(CMG-2), collectively referred to as anthrax toxin receptors (ANTXRs). Both TEM-8
and CMG-2 show a high degree of similarity; they are ubiquitously expressed type-1
transmembrane proteins, with each having an ectodomain (extracellular domain), a
single-pass transmembrane domain and a cytoplasmic domain. The gene Cmg2 is
expressed all over the human body with the exception of the human brain, however the
exact role Cmg2 is still largely unknown. TEM-8, being a tumor marker on one hand,
might also play a role in angiogenesis since both Tem8 and Cmg2 genes have been found
to be upregulated during angiogenesis (Deuquet J, 2012).
Following binding to its receptors, PrAg is cleaved at the sequence, 164RKKR167, by
cell surface furin-like proteases leading to the release of a 20-kDa fragment and the
generation of an active 63-kDa fragment (PrAg63) (Abi-Habib RJ U. J., 2005) (Abrami L
L. S., 2003). The latter then forms oligomers, bind 3-4 molecules of LF and undergo
receptor-mediated endocytosis (Abrami L L. S., 2006).Upon acidification of the
endosome, PrAg63 oligomers undergo a conformational change leading to a cation-
dependent pore formation and allowing LF to translocate into the cytosol (Melnyk PA,
2006) . LF is a zinc metalloprotease that cleaves and inactivates all mitogen-activated
protein/extracellular regulated kinase kinases (MEKs), leading to the inhibition of the
7
MAPK pathway and subsequent growth inhibition and cell death. (Duesbery NS, 1998)
(Chopra AP, 2003) (Abi-Habib RJ S. R., 2006)
Figure 2. Mechanism of action of Anthrax Toxin (Moayeri, 2004)
We have previously shown that cytotoxicity of LeTx to human melanoma cell lines
carrying the V600E BRAF mutation is dependent on the activation status of the MAPK
pathway, particularly MEK1/2, allowing the use of this toxin for the selective targeting of
tumors with constitutive MAPK activation (Koo HM, 2002) (Abi-Habib RJ U. J., 2005)
(Wu, 2004) (Milella M K. S., 2001) (Abi-Habib RJ S. R., 2006)
8
1.5 Previous work
We and others have previously demonstrated the potency and selectivity of LeTx to
melanoma cell lines in vitro and in an in vivo melanoma model (Abi-Habib RJ U. J.,
2005) (Koo HM, 2002). However, unlike melanoma, in which the importance of N-Ras
and BRAF mutations (found in up to 95% of cases) is well established, the importance of
MAPK pathway mutations in AML has been poorly investigated (Zaidi SK, 2009).
Moreover, very few attempts have been made to target the MAPK pathway in AML, with
the exception of targeting the receptor tyrosine kinase FLT3 (fms-like tyrosine kinase) in
AML cells carrying FLT3 mutations (Ricciardi M, 2012) (Konopleva M, 2005). Hence, a
deeper investigation of the role played by the MAPK pathway in human AML cell lines
along with the possibility of selectively targeting AML through the inhibition of the
MAPK pathway are warranted.
In this study, we attempt to target the MAPK pathway in AML cell lines using a
recombinant anthrax lethal toxin and to characterize the response of AML cells to the
LeTx-mediated inhibition of the MAPK pathway.
9
CHAPTER TWO
MATERIALS AND METHODS
Expression and purification of PrAg, LF and FP59:
Recombinant anthrax lethal toxin (LeTx) proteins PrAg and LF, as well as FP59 (fusion
of the PrAg binding domain of LF and the catalytic domain of Pseudomonas aeruginosa
exotoxin A) were expressed and purified in the laboratory of Stephen H. Leppla at the
National Institute of Allergies and Infectious Diseases (NIAID) of the National Institutes
of Health (NIH) in Bethesda, MD, as described previously (Ramirez DM, 2002) (Liu S,
2001). Briefly, fermentation was carried out by inoculating a 12 to 14 h old starter culture
grown from a frozen stock. Three to ten liter fermentations were carried out controlling
dissolved oxygen (DO) at 30% saturation, temperature at 37oC, and pH at 7.5. At harvest
time, 5 mM EDTA and 10 ug/ml PMSF (phenylmethyl sulfonyl fluoride) were added to
the culture. Purification was then carried out as follows: 1. Packed-bed hydrophobic
interaction chromatography during which the cell suspension was centrifuged and the
supernatant was passed through a 0.2 -µm hollow fiber filter (AGT, Needham, MA). The
filtered broth was then concentrated 20 fold using a 10K membrane. After sample
loading, the column was washed with 10 column volumes (CV) of equilibration buffer
and rPA was eluted with a 30 CV linear gradient of (NH4)2SO4 in 10 mM HEPES, 5
mM EDTA. The rPA-containing fractions were pooled for further purification. 2-
Expanded-bed hydrophobic interaction chromatography in which the cell suspension was
diluted 1:1 with buffer and the diluted cell suspension was loaded upward at 300 cm/ h.
The column was washed in expanded mode with 10 CV of equilibration buffer. Elution
10
was performed in packed-bed mode with 8 CV of elution buffer at 100 cm/ h. 3- Anion
exchange chromatography in which fractions from HIC were dialyzed against 20 mM
Tris pH= 8.9/ 5 mM EDTA and loaded on a Q Sepharose Fast Flow (Amersham
Pharmacia Biotech) column. The protein was eluted using a 20 CV linear gradient of
NaCl in the same buffer. rPA-containing fractions were concentrated and dialyzed against
PBS. (Ramirez DM, 2002) (Liu S, 2001)
LY294002 was purchased from Cell signaling Technology (Danvers, MA).
Cells and cell lines:
Human AML cell lines HL60, U937, ML2, Mono-Mac-1, Mono-Mac-6, KG-1, SigM5,
TF1-vRaf, TF1-vSrc and TF1-HaRas were grown in RPMI 1640 medium with 10% heat-
inactivated fetal bovine serum supplemented with penicillin/streptomycin and l-
glutamine. ML1 was grown in Iscove’s modified Dulbecco’s medium with 10% heat-
inactivated fetal bovine serum (FBS) supplemented with penicillin/streptomycin and l-
glutamine (Ramage J, 2003).24
Cells were maintained in a water-jacketed CO2 incubator
at 37oC/5%CO2 and passaged every 2 to 3 days into new flasks containing fresh media.
Human CD34+ progenitor bone marrow blasts (PBMBs) were purchased from (Lonza,
Basel, Switzerland) and grown in StemlineIITM
hematopoietic stem cell expansion
medium (Sigma-Aldrich) supplemented with 10 ng/ml IL-3, 5 ng/ml granulocyte colony
stimulating factor (G-CSF), 5 ng/ml granulocyte macrophage colony stimulating factor
(GMCSF), 10 ng/ml stem cell factor (SCF), 10 µg/ml insulin and 100 µg/ml transferrin
(Sigma-Aldrich), as described previously (Blair A, 1998).
11
Proliferation inhibition assay (cytotoxicity):
Sensitivity of AML cell lines and CD34+
Progenitor Bone Marrow Blasts (PBMBs) to
LeTx was determined using a proliferation inhibition assay as described previously (Abi-
Habib RJ U. J., 2005) We have also used a recombinant protein, termed FP59, consisting
of the PrAg binding domain of LF fused to the catalytic domain of Pseudomonas
aeruginosa exotoxin A. Binding of FP59 to PrAg and its translocation into the cytosol are
identical to those of LF, however, it does not target the MAPK pathway but rather ADP-
ribosylates elongation factor 2 (EF-2) leading to inhibition of protein synthesis and cell
death. PrAg/FP59 was used as a control for catalytic domain entry into the cytosol of
AML cells. Briefly, aliquots of 104 cells/well, in 100 l cell culture medium, containing a
fixed concentration of 10-9
M LF or FP59, were plated in a flat-bottom 96-well plate
(Corning Inc. Corning, NY). Then, 50 l PrAg in media were added to each well to yield
concentrations ranging from 10-8
to 10-13
M. When LY294002 or U0126 were used, they
were added as described above for PrAg but in concentrations ranging from 10-4
to 10-9
M. Following a 48 h incubation at 37oC/5% CO2, 50 l of XTT cell proliferation reagent
(Roche, Basel, Switzerland) were added to each well and the plates incubated for another
4 h. Absorbance was then read at 450 nm using a microplate reader (Thermo Fisher
Scientific, Waltham, MA). Nominal absorbance and percent maximal absorbance were
plotted against the log of concentration and a non-linear regression with a variable slope
sigmoidal dose-response curve was generated along with IC50 using GraphPad Prism 5
software (GraphPad Software, San Diego, CA). All assays were performed at least twice
with an inter-assay range of 30% or less for IC50.
12
Cell cycle analysis:
The impact of LeTx treatment on the cell cycle of AML cells was determined using
Propidium Iodide (PI)-staining on flow cytometry. Briefly, cells incubated with 3
different concentrations of LeTx (10,000, 300 and 4.5 pM) or media alone in flat-bottom
96-well plates (Corning Inc. Corning, NY) for 24 and 48 h at 37oC/5% CO2, were
harvested and fixed in 70% ethanol for a minimum of 24 h, at -20oC. Cells were then
incubated in 500 l PI staining solution (50 µg/ml) for 40 min at 37oC. Samples were
then read on a C6 flow cytometer (BD Accuri, Ann Arbor, MI) and total cell DNA
content was measured on FL2-A. Percent of cells in G0/G1, S and G2/M phase was
determined in control cells and in cells treated with the 3 different concentrations of LeTx
(10,000, 300 and 4.5 pM) following gating for the cell population on width versus
forward scatter.
Inhibition Assays
AML cells were incubated with either the small molecular weight PI3 kinase (PI3K)
inhibitor LY294002 (Cell Signaling Technology, Danvers, MA) alone and in
combination with LeTx or with the small molecular weight MEK1/2 inhibitor U0126
(Cell Signaling Technology, Danvers, MA). Briefly, 104 cells/well were plated in 100 l
of medium in a flat-bottom, 96-well plate. Then 100 l of either medium (control cells)
or medium containing LeTx (10-8
M PrAg/10-9
M LF), LY294002 (20 and 50 µM), U0126
(20 and 50 µM) or a combination of the above were added. Cells were then incubated for
48 h at 37oC/5% CO2 followed by the addition of 50 l of XTT cell proliferation reagent
(Roche, Basel, Switzerland). Cells were incubated for another 4 h and absorbance was
read at 450 nm using a 96-well plate reader (Thermo Fisher Scientific, Waltham, MA).
13
Data was analyzed using GraphPad Prism V software (GraphPad Software, San Diego,
CA). The absorbance and the percent absorbance of controls were compared between the
different treatment groups.
Protein Extraction and Western Blotting
10 x 106
cells of each of the 11 cell lines were isolated, centrifuged at 1500 rpm for 5
min. Cells were then re-suspended in Cell Lytic™ Mamalian Cell Lysis Reagent (Sigma-
Aldrich) with 1% protease inhibitor (M221, Protease Inhibitor Cocktails, Amresco, USA)
then centrifuged at 1500 rpm for 5 min. The supernatant was collected and stored at -80
oC. All protein samples used for western blotting were prepared in the same way; 8 l of
each sample were added to 10 l of Protein Loading buffer (ProSieve®ProTrack™ Dual
Color, Lonza, Rockland USA) and 2 l DTT, for a total of 20 l. 10% polyacrylamide
precast 10-well gels (Bio-Rad) were used. 10 l of a Biotinylated protein ladder (Cell
Signaling Technology, Danvers, MA) was loaded in the first well. Bio-Rad Mini-
PROTEAN® Tetra System Electrophoresis apparatus was used for running at 120 Volts
and transfer at 0.25 mA on nitro-cellulose membrane. Running buffer used consisted of
60% glycine, 30% Tris-base and 10 % SDS at a pH of 8.4. The transfer buffer used was
prepared using 20% running buffer with 20% methanol and 60% distilled water. The
membranes were blocked overnight using 5% BSA and 0.1% Tween 20. The membranes
were then incubated for 1 hour with the primary anti-phospho-ERK1/2 (Ser217/221) or
anti-ERK1/2 (Thr202/Tyr204) rabbit monoclonal antibodies (Cell Signaling Technology,
Danvers, MA) in antibody binding buffer, and then washed using a washing buffer (TBS
+ 0.5% Tween 20) three times each for 15 min. After washing, the membranes were
incubated with the secondary FITC-conjugated mouse anti-rabbit polyclonal antibody
14
(Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hr and then washed three times for 15
min as described before. Development was done using Bio-Rad Molecular Imager®
(ChemiDoc™XRS+, bio-Rad USA) Imaging System. Band intensity was analyzed using
Quantity One® Software (Bio-Rad Laboratories, Inc., ©1998, version 4.6.9.30) and the
ratio of Phospho ERK to ERK was determined.
Intracellular Staining and Flow Cytometry Analysis
Activation of the MEK1/2-ERK1/2 pathway in AML cell lines [untreated and following a
10-hour incubation with LeTx (10-8M PrAg/10-9M LF)] was assessed by determining
the presence or absence of phospho-ERK1/2 using flow cytometry as described
previously.25
Approximately 3x106 cells were fixed in 70% ethanol for 15 min. Cells
were then incubated with a 1/100 dilution of anti-phospho-ERK1/2 (Ser 217/221) rabbit
monoclonal antibodies (Cell Signaling Technology, Danvers, MA) in antibody binding
buffer containing 0.05% Triton-X 100, for 1 h at 37oC, followed by a 30-minute
incubation with a 1/100 dilution of a FITC-conjugated mouse anti-rabbit polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Fixed cells stained only with
FITC-conjugated mouse anti-rabbit polyclonal antibody were used as isotypic control.
Samples were then analyzed using a C6 flow cytometer (BD Accuri, Ann Arbor, MI).
The presence of Phospho-ERK1/2 was analyzed and compared with that of the isotopic
control. Positivity for the presence of phospho-ERK1/2 was determined using the ratio of
fluorescence intensity (RFI) between the mean fluorescence intensity (MFI) of the
stained cells and the MFI of the isotypic control. RFI 2 was considered positive.
15
Analysis of Cell Cytotoxicity:
Determination of apoptotic versus non-apoptotic cell death was carried out using an
Annexin V-fluorescin Isothiocyanate (Annexin V-FITC) and Propidium Iodide (PI)
labeled apoptosis/necrosis detection kit (Abcam, Cambridge, MA) and a FITC-
conjugated active caspase inhibitor (ApoStat Apoptosis Detection Kit, R&D Systems,
Abingdon, England) on flow cytometry. Briefly, 104 cells/well were plated in 100 l
media in a flat-bottom, 96-well plate and were incubated with either 100 l of medium
alone (control cells) or medium containing three different concentrations of LeTx (as
described above under cell cycle analysis) for 24 and 48 h at 37oC/5% CO2. Cells were
then harvested and incubated with a FITC-conjugated annexin V antibody (2.5 mg/ml
and PI (5 mg/ml) in antibody binding buffer for 45 min at 37oC or incubated with 0.5
µg/ml of apostat for 30 min then harvested. Cells were then read using a C6 flow
cytometer. Annexin V/PI data was analyzed on FL1-H versus FL2-H scatter plot and
active caspases were detected on FL1-H. Unstained cells were used as negative control.
Cells had to show positive annexin V staining, negative PI staining and positive active
caspase staining to be considered apoptotic, while cells positive for both annexin V and
PI staining and negative for active caspase staining were considered non-apoptotic.
16
CHAPTER THREE
RESULTS
Cytotoxicity of Anthrax Lethal Toxin:
We tested the cytotoxicity of anthrax lethal toxin (LeTx) on a panel of 11 human acute
myeloid leukemia (AML) cell lines using an XTT proliferation inhibition assay. Seven
out of eleven AML cell lines (64%) were sensitive to the LF-mediated inhibition of the
MAPK pathway with IC50 values ranging from 13 to94 pM and percent cell kill at highest
concentration > 75%. The remaining 4 cell lines were not sensitive to the LF-mediated
inhibition of the MAPK pathway with IC50 > 10,000 pM and percent cell kill at highest
concentration ≤ 40% (Table 1, Fig. 3F). Human CD34+ Progenitor Bone Marrow Blasts
(PBMBs), on the other hand, were not sensitive to the LeTx-mediated inhibition of the
MAPK pathways indicating that LeTx selectively targets AML cells while sparing
normal progenitor blasts. To demonstrate that resistance to LeTx was due to resistance to
the LF-mediated inhibition of the MAPK pathway and not to the inability of LF to
translocate into the cytosol of targeted cells, we tested the cytotoxicity of a combination
of PrAg and FP59 to AML cell lines. FP59 is a fusion of the PrAg binding domain of LF
and the catalytic domain of Pseudomonas aeruginosa exotoxin A. Binding to PrAg and
translocation of FP59 into the cytosol are identical to those of LF, however, FP59 does
not target the MAPK pathway but rather ADP-ribosylates elongation factor 2 (EF-2)
leading to the inhibition of protein synthesis and subsequent cell death. The combination
of PrAg and FP59, therefore, induces MAPK-independent cytotoxicity to all cells that
express the anthrax toxin receptors. PrAg/FP59 was cytotoxic to all the AML cell lines
17
tested with IC50 = 0.7-18 pM and percent cell death > 90% indicating that differential
sensitivity of AML cells to LeTx is independent of the ability of LF to translocate into the
cytosol (Table 1, Figure 3A-D) and dependent on the addiction of cells to the MAPK
pathway.
Table 1. Sensitivity of human AML cell lines to LeTx (PrAg/LF), U0126 and the protein
synthesis inhibitor PrAg/FP59.
Cells and Cell
lines
LeTx (PrAg/LF)
(IC50;pmol/L)
PrAg/FP59
(IC50;pmol/L)
U0126
(IC50;µmol/L)
AML Cell lines
HL60 13.0 0.7 2.6
TF1-VSrc 15.0 3.0 2.0
TF1-VRaf 16.0 4.0 1.3
Mono-Mac-6 39.0 13.0 2.1
SigM5 40.0 17.0 1.9
ML-2 81.0 7.0 1.5
TF1-HaRas 94.0 0.4 2.7
ML-1 > 10000 6.0 > 1000
U937 > 10000 1.0 > 1000
KG-1 > 10000 1.0 > 1000
Mono-Mac-1 > 10000 2.0 > 1000
Normal Cells
CD34+ BMPBs > 10000 10.0 N/A
N/A: Not available
18
In addition, intracellular staining and flow cytometry analysis of phospho-ERK1/2 in
sensitive cell lines before and after a10h incubation with LeTx revealed the absence of
phospho-ERK1/2 in cells treated with LeTx, compared to non-treated cells, thus
indicating that cytotoxicity of LeTx to AML cells is mediated through the proteolytic
cleavage of MEKs by LF and subsequent inhibition of the MAPK pathway as evidenced
by the absence on phospho-ERK1/2 in LeTx-treated cells (Data not shown). Moreover,
since anthrax lethal toxin inhibits all branches of the MAPK pathway, it is possible that
cytotoxicity of LeTx to AML cell lines is due to the simultaneous inhibition of all three
branches of the MAPK pathway and not only the MEK1/2-ERK1/2 branch. Therefore, in
order to determine the contribution of the MEK1/2-ERK1/2 branch to the cytotoxicity of
LeTx, we tested the sensitivity of our panel of AML cell lines to U0126, the specific
MEK1/2 inhibitor. Cytotoxicity of U0126 mimicked that of LeTx with the same pattern
seen with both LeTx and U0126 across the panel of AML cell lines (Table 1, Figure 3G).
A)
HL60
-14 -13 -12 -11 -10 -9 -8 -70.0
0.5
1.0
1.5
2.0
2.5
PrAg/LF
PrAg/FP59
Log [M]
Ab
so
rba
nc
e
19
B)
TF1-vRaf
-14 -13 -12 -11 -10 -9 -8 -70.0
0.5
1.0
1.5
2.0
2.5
PrAg/FP59
PrAg/LF
Log [M]
Ab
so
rba
nc
e
C)
Mono-Mac-1
-14 -13 -12 -11 -10 -9 -8 -70.0
0.2
0.4
0.6
0.8
1.0
PrAg/FP59
PrAg/LF
Log [M]
Ab
so
rba
nc
e
D)
U937
-14 -13 -12 -11 -10 -9 -8 -70.0
0.5
1.0
1.5
2.0
2.5
PrAg/LF
PrAg/FP59
Log [M]
Ab
so
rba
nc
e
20
E)
CD34+ PBMBs
-14 -13 -12 -11 -10 -9 -8 -70.4
0.6
0.8
1.0
PrAg/FP59
PrAg/LF
Log [M]
Ab
so
rba
nce
F)
LeTx
-14 -13 -12 -11 -10 -9 -8 -70
20
40
60
80
100
120
TF1-vRaf
TF1-HaRas
TF1-vSrc
MonoMac-1
MonoMac-6
U937
HL60
KG-1
ML-2
ML-1
Sig-M5
Log [M]
Perc
en
t C
on
trol
G)
U0126
-10 -9 -8 -7 -6 -5 -4 -30
20
40
60
80
100 TF1-vRaf
HL60
Mono-Mac-1
U937
Log [M]
Pe
rce
nt
Co
ntr
ol
21
Figure 3. Non-Linear regression curves of LeTx (PrAg/LF) (square) and PrAg/FP59
(triangle) on human AML cell lines and normal CD34+ BMPBs. HL60 (A) and TF1-vRaf
(B) cell lines are sensitive to both LeTx and PrAg/FP59. Mono-Mac-1 (C), U937 (D) and
CD34+ BMPBs (E) are only sensitive to PrAg/FP59 but not to PrAg/LF indicating
resistance to the LF-mediated inhibition of the MAPK pathway. F) Compilation of LeTx
non-linear regression curves on all AML cell lines tested. G) Non-linear regression
curves of the specific MEK1/2 inhibitor U0126 on TF1-vRaf (square), HL60 (triangle),
Mono-Mac-1 (inverted triangle) and U937 (diamond) cell lines. The LeTx-sensitive cell
lines TF1-vRaf and HL60 are sensitive to U0126 while the LeTx-resistant cell lines
Mono-Mac-1 and U937 are resistant to U0126.
The four cell lines that were resistant to LeTx-induced cytotoxicity were also resistant to
U0126 (IC50 > 1000 µM and percent cell kill at the highest concentration ≤ 35%), thus
confirming that these cell lines do not rely on the MAPK pathway for survival and are
resistant to both the specific inhibition of MEK1/2 and the inhibition of the entire MAPK
pathway. The seven AML cell lines that were sensitive to LeTx-induced cytotoxicity
were also sensitive to the specific MEK1/2 inhibitor U0126 (IC50 = 1.3-2.7 µM, percent
cell kill at the highest concentration > 60%), thus indicating that cytotoxicity of LeTx is
mediated through the inhibition of the MEK1/2-ERK1/2 branch of the MAPK pathway.
Cell cycle effect of Anthrax Lethal Toxin:
In order to determine whether, in addition to its cytotoxicity, LeTx induces cell cycle
arrest in AML cells, we determined the cell cycle status of our panel of AML cell lines
following 24 and 48 h incubation with three different concentrations of the LeTx. One of
the four AML cell lines that were not sensitive to the cytotoxicity of LeTx (ML1) showed
dose-dependent cell cycle arrest at 24 h (data not shown) and 48 h following treatment
with LeTx, while the other three (U937, Mono-Mac-1 and KG-1) did not show any effect
22
of LeTx treatment on cell cycle (Fig. 4A and B). The fraction of cells in the G0/G1 phase
of ML1 increased from approximately 39% and 34% of the total cell population in
control cells to approximately 74% and 60% of the total cell population following
incubation with 10,000 pM of LeTx for 24 and 48 h, respectively. This was associated
with a corresponding decrease in the percentage of cells in the G2/M phase from
approximately 10% and 19% of the cell population in control cells to approximately 7%
and 8% of the cell population in treated cells at 24 and 48 h, respectively (Fig. 4A).
A)
23
B)
C)
24
D)
E)
25
F)
Figure 4. Cell cycle analysis of AML cell lines following treatment with LeTx. Control
cells are represented in the left panels and cells treated with 10 nM LeTx for 48 h in the
right panels. Cells are gated on width versus forward scatter (R1/R2). Cells in G0/G1 are
gated M2, G2/M are gated M3 and pre-G0/G1 (dead) are gated M4 or M5. One of the cell
lines that did not show a cytotoxic response to LeTx, ML1 (A), did show cell cycle arrest
while the other, U937 (B), did not. Similarly, three of the LeTx-sensitive cell lines ML2
(C), HL60 (D) and TF1-HaRas (E) showed cell cycle arrest in addition to cell death while
another, TF1-vRaf (F), showed complete cell death following treatment.
Furthermore, cell cycle arrest was observed in four out of the seven cell lines that showed
a cytotoxic response to the LF-mediated inhibition of the MAPK pathway (ML2, HL60,
TF1-HaRas and TF1-vSrc) at 24 h (data not shown) and 48 h following treatment with
LeTx. A dose-dependent increase in the percentage of surviving cells in the G0/G1 phase
was observed (42%, 58%, 41% and 40% in control cells versus 54%, 70%, 67% and 54%
in treated cells) at 48 h, in ML2, HL60, TF1-HaRas and TF1-vSrc cells, respectively
(Fig. 4C, D and ). This was associated with a corresponding decrease in the percentage of
cells in the G2/M phase, by approximately 10%, in treated versus control cells in all four
cell lines. The remaining three LeTx-sensitive cell lines [TF1-vRaf (Fig. 4D), SigM5 and
26
Mono-Mac-6], showed complete cell death with more than 90% of cells in the pre-G0/G1
peak and no difference in the percentage of cells in the G0/G1 phase between control
cells and surviving cells at the highest concentration of LeTx at both 24 h (data not
shown) and 48-h incubation. This indicates that, in addition to significant cytotoxicity to
the majority of AML cell lines, LeTx induces cell cycle arrest in a subset of AML cells
(approximately 45%) irrespective of their cytotoxic response to the LF-mediated
inhibition of the MAPK pathway.
Inhibition of PI3 Kinase:
In order to determine whether AML cell lines that are resistant to the LF-mediated
inhibition of the MAPK pathway are susceptible to the inhibition of the PI3K/Akt
pathway, we tested the sensitivity of the LeTx-resistant cell lines (ML1, Mono-Mac-1,
U937 and KG-1) to the small molecular weight PI3K inhibitor LY294002. Incubation
with LY294002 at 20 and 50 µM for 48 h induced significant cytotoxicity in all four cell
lines with cell viability decreasing by approximately 40 to 50% at the 20 M
concentration and 60 to 80% at the 50 M concentration compared to untreated cells (p <
0.05) (Fig. 5A). Co-incubation of these cells with both LeTx (10 nM) and LY294002 (20
and 50 M) led to only a slight decrease in cell viability, approximately 10%, compared
to LY294002 alone. Although the decreases in cell viability observed following co-
incubation with both LeTx and LY294002 were statistically significant for the U937 cell
line at the 20 M concentration, the ML1 cell line at the 50 M concentration and the
Mono-Mac-1 and KG-1 cell lines at both the 20 and 50 M concentrations (P < 0.05),
compared to LY294002 alone, they were not considered functionally significant since co-
27
incubation only accounted for an additional decrease in cell viability of no more than
10% compared to LY294002 alone (Fig. 5A). Moreover, cytotoxicity of the combination
of LY294002 and LeTx was similar to the cytotoxicity of either LeTx alone or LY294002
alone as evidenced by similar non-linear regression curves and similar IC50 values, at 48
h, in a proliferation inhibition assay (Fig. 5 B, C and D).
A)
U937
Contr
ol
LeTx
(10n
M)
M)
LY2940
02 (2
0M
)
LeTx
(10n
M) +
LY (2
0M
)
LY2940
02 (5
0M
)
LeTx
(10n
M) +
LY (5
0
0
20
40
60
80
100
Pe
rce
nt
Con
tro
l
Mono-Mac-1
Contr
ol
LeTx
(10n
M)
M)
LY2940
02 (2
0M
)
LeTx
(10n
M) +
LY (2
0M
)
LY2940
02 (5
0M
)
LeTx
(10n
M) +
LY (5
0
0
20
40
60
80
100P
erc
en
t C
on
tro
l
ML1
Contr
ol
LeTx
(10n
M)
M)
LY2940
02 (2
0M
)
LeTx
(10n
M) +
LY (2
0M
)
LY2940
02 (5
0M
)
LeTx
(10n
M) +
LY (5
0
0
20
40
60
80
100
Pe
rce
nt
Con
tro
l
KG-1
Contr
ol
LeTx
(10n
M)
M)
LY2940
02 (2
0M
)
LeTx
(10n
M) +
LY (2
0M
)
LY2940
02 (5
0M
)
LeTx
(10n
M) +
LY (5
0
0
20
40
60
80
100
Pe
rce
nt
Co
ntr
ol
28
B)
U937
-14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -30.0
0.5
1.0
1.5
2.0PrAg/LF
LY294002
PrAg/LF+LY294002
Log [M]
Ab
so
rba
nc
e
C)
Mono-Mac-1
-14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -30.0
0.2
0.4
0.6
0.8
1.0
PrAg/LF
LY294002
PrAg/LF+LY294002
Log [M]
Ab
so
rba
nc
e
D)
TF1-vSrc
-14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -30.0
0.5
1.0
1.5
2.0
2.5
PrAg/LF
LY294002
PrAg/LF+LY294002
Log [M]
Abs
orb
anc
e
29
Figure 5. Sensitivity of LeTx-resistant AML cell lines to LY294002 alone and in
combination with LeTx. A) LeTx resistant cell lines incubated with LY294002 at 20 and
50 µM, for 48 h were sensitive to both concentrations of LY294002 while co-incubation
with LeTx (10 nM) did not lead to any significant increase in sensitivity cell sensitivity.
Non-linear regression curves of U937 (B), Mono-Mac-1 (C) and TF1-vSrc (D) cells
incubated with LeTx (square), LY294002 (triangle) or a combination of both (inverted
triangle). The combination of LeTx and LY294002 did not lead to increased cytotoxicity
compared to either LeTx or LY294002 alone.
Hence, cell lines that are not sensitive to LeTx are sensitive to the inhibition of the
PI3K/Akt pathway with the simultaneous inhibition of both pathways not resulting in
increased cell cytotoxicity. This shows the existence of two distinct populations of AML
cell lines sensitive to the inhibition of either the MAPK pathway or the PI3K/Akt
pathway with no additive or synergistic effect observed when both pathways are inhibited
simultaneously.
Analysis of MAPK Activation:
We examined the activation level of the MAPK pathway in AML cell lines by
determining the phosphorylation status of phospho-ERK1/2, using both single-cell
intracellular staining on flow cytometry and western blotting. A representative sample of
four AML cell lines was tested using single-cell intracellular staining, while lysates of the
entire panel of AML cell lines were tested by western blot to determine the ratio of
phosphor/total ERK1/2 levels.The presence or absence of phospho-ERK1/2 was linked to
the cells response to the LF-mediated inhibition of the MAPK pathway.
Both of the cell lines that showed a cytotoxic response to the LF-mediated inhibition of
the MAPK pathway (ML-2 and TF1-vRaf) had an active MEK1/2-ERK1/2 pathway as
30
evidenced by the presence of phospho-ERK1/2 using single-cell intracellular staining
(RFI = 2.14 and 2.32 for ML-2 and TF1-vRaf, respectively, compared to isotype control)
(Fig. 6 A and B).
A) B)
C) D)
Figure 6. Single-cell, intracellular staining of Phospho-ERK1/2 in 4 AML cell lines
using flow cytometry. TF1-vRaf (A) and ML-2 (B) cells, which showed a cytotoxic
response to the LF-mediated inhibition of the MAPK pathway, were positive for the
31
presence of phospho-ERK1/2 as evidenced by a ratio of fluorescence intensity (RFI) > 2
between cells stained for phospho-ERK1/2 (grey) and cells incubated with an isotype
control (black). Cells are gated on width versus forward scatter (R2 and R3). ML-1 (C)
and U937 (D) cells, which were resistant to the cytotoxicity of LeTx, were negative for
phospho-ERK1/2 with RFI < 1.5.
On the other hand, the two cell lines that did not show a cytotoxic response to the LF-
mediated inhibition of the MAPK pathway (U937 and ML-1) were not positive for the
presence of phospho-ERK1/2, hence had an inactive MEK1/2-ERK1/2 pathway (RFI =
1.41 and 1.51 for U937 and ML-1, respectively, compared to isotype control) (Fig. 6 C
and D).
Analysis of the ratio of phospho to total ERK1/2 in cell lysates of AML cell lines, an
indicator of the activation level of the Ras-Raf-MEK1/2-ERK1/2 branch of the MAPK
pathway, revealed the presence of a higher ratio of phospho to total ERK1/2 in AML cell
lines sensitive to the LeTx-induced inhibition of the MAPK pathway (mean ratio 0.74)
compared to cells resistant to the inhibition of this pathway (mean ratio 0.49) (Table 2).
32
Table 2. Sensitivity of human AML cell lines to LeTx (PrAg/LF) and activation level of
the MAPK pathway illustrated by the ratio of phospho to total ERK1/2 levels.
Cell line LeTx (PrAg/LF)
(IC50;pmol/L)
Ratio of Phospho to total
Erk1/2
HL60 13.0 1.00
TF1-VSrc 15.0 0.74
TF1-VRaf 16.0 0.73
Mono-Mac-6 39.0 0.70
SigM5 40.0 N/A
ML-2 81.0 0.27
TF1-HaRas 94.0 1.00
ML-1 > 10000 0.31
U937 > 10000 0.54
KG-1 > 10000 N/A
Mono-Mac-1 > 10000 0.62
N/A: Not Available
As illustrated in Table 2, all the LeTX-sensitive AML cell lines, except ML-2, had a ratio
of phospho to total ERK1/2 higher than 0.7 indicating that more than 70% of total
ERK1/2 in those cells is in the phosphorylated form, demonstrating a high level of
activity of the MEK1/2-ERK1/2 branch of the MAPK pathway which correlates with the
sensitivity of those cells to the inhibition of the MAPK pathway. On the other hand,
33
LeTx-resistant cell lines had a relatively lower activation level of the MEK1/2-ERK1/2
branch of the MAPK pathway, as illustrated by lower ratios of phospho to total ERK1/2,
which correlates with their resistance to the inhibition of that pathway.
This indicates that phospho-ERK1/2 levels, which reflect the activation level of the
MAPK pathway, may serve as a useful marker for predicting the sensitivity of AML cells
to the inhibition of the MAPK pathway. However, as illustrated by the low ratio of
phospho to total ERK1/2 in one of the LeTx-sensitive cell lines (ML2, 0.27) and the
relatively high ratio in one of the LeTx-resistant cell lines (Mono-Mac-1, 0.6), the
addiction of a tumor cell to a particular signaling pathway, i.e. its inability to survive its
inhibition, is much more complex than its simple activation level in that cell.
Analysis of Cell Death:
To determine the mechanism of the cell death observed following the LF-mediated
inhibition of the MAPK pathway in AML cells, we tested for caspase activation and
annexin V/PI staining in our panel of AML cell lines following treatment with three
different concentrations of LeTx (10,000, 300 and 4.5 pM) for 24 and 48 h. The four cell
lines that did not show a cytotoxic response following treatment with LeTx in the
proliferation inhibition assay, stained negatively with both PI and Annexin V, confirming
the absence of cell death following LF-mediated inhibition of the MAPK pathway in
these cell lines. On the other hand, in all seven LeTx-sensitive cell lines (TF1-vRaf, TF1-
vSrc, TF1-HaRas, HL60, SigM5, Mono-Mac-6 and ML-2), an increase in the percentage
of cells stained with both annexin V and PI was observed, at both 24 and 48 h, in cells
treated at the highest concentration of LeTx (10 nM) compared to controls, indicating
34
either necrotic or late-stage apoptotic cell death (Fig,7). However, staining for active
caspases revealed a total absence of caspase activation in all AML cell lines tested,
following treatment with LeTx for 24 and 48 h (Fig. 7). The absence of caspase
activation, in addition to the loss of membrane integrity as evidenced by positive PI
staining, indicate that LeTx-induced cytotoxicity in AML cells is mediated through
caspase-independent, non-apoptotic mechanisms.
A)
35
B)
C)
Figure 7. Analysis of the mechanism of LeTx-mediated cytotoxicity in TF1-vRaf cells
using annexin V/PI (A) and active caspase staining (B) and in HL60 cells using annexin
V/PI (C). TF1-vRaf and HL60 cells incubated with 10 nM LeTx for 24 or 48 h (right
panel) stained positively with both annexin V (FL1-H) and PI (FL2-H). Incubation of
LeTx-treated TF1-vRaf cells with a cell permeable, FITC-conjugated active caspase
inhibitor revealed the absence of active caspases following incubation with LeTx (grey).
36
CHAPTER FOUR
DISCUSSION
In this study, we have shown that anthrax lethal toxin (LeTx) is highly cytotoxic to a
majority of human AML cell lines through the LF-mediated inhibition of the MAP kinase
pathway. Limited information exists regarding the importance of the MAPK pathway in
AML cells and the potential targeting of AML through the inhibition of the MAPK
pathway has not been sufficiently investigated so far (Zaidi SK, 2009) (Ricciardi M,
2012) (Konopleva M, 2005). We have demonstrated that differential sensitivity of AML
cell lines to anthrax lethal toxin was not due to the inability of the LF moiety to
translocate into the cytosol, but rather to the differential sensitivity of AML cell lines to
the LF-mediated inhibition of the MAP kinase pathway. When we replaced the catalytic
domain of LF with the catalytic domain of Pseudomonas aeruginosa exotoxin A, which
inhibits protein synthesis rather than the MAPK pathway, differential sensitivity was lost
and all AML cell lines tested were sensitive to the combination of PrAg and FP59,
demonstrating that differential sensitivity of AML cells to LeTx was due to the
differential response of AML cell lines to the LF-mediated inhibition of the MAPK
pathway. In addition, we have shown that the pattern of cytotoxicity of LeTx on our
panel of AML cell lines was mimicked by the specific, small molecular weight MEK1/2
inhibitor U0126, indicating that cytotoxicity of LeTx is mainly mediated through the
inhibition of the MEK1/2-ERK1/2 branch of the MAPK pathway. Moreover, we have
shown that incubation of AML cells with LeTx leads to a marked inhibition of the
MEK1/2-ERK/12 branch of the MAPK pathway as evidenced by the absence of
37
phosphorylated ERK1/2 in cells incubated with LeTx for 10h as compared to non-treated
cells.
The four AML cell lines that proved to be resistant to the inhibition of the MAPK
pathway by LeTx were sensitive to the inhibition of the PI3K/AKT pathway by
LY294002, a small molecular weight PI3 kinase inhibitor. Interestingly, co-incubating
AML cell lines with both LeTx and LY294002 did not show any significant increase in
cytotoxicity compared to LY294002 alone. Therefore, the panel of AML cell lines tested
consisted of two distinct populations, one sensitive to the inhibition of the MAPK
pathway, the other sensitive to the inhibition of the PI3/AKT pathway with the
simultaneous inhibition of both pathways not leading to any additive or synergistic
effects. These findings are surprising since the inhibition of both the MEK1/2-ERK1/2
pathway and the PI3K/Akt pathway has been shown to have additive or synergistic
effects in a number of tumor types, including hepatocellular carcinoma, colorectal cancer,
pancreatic adenocarcinoma and melanoma (Shimizu T, 2012) (Gedaly R, 2012)
(Haagensen EJ, 2012) (Williams TM, 2012) Moreover, it has been shown that resistance
to MEK inhibitors is mediated through the activation of the PI3k/Akt pathway in a
number of tumors (Wee S, 2009).30
Inhibition of both the MEK1/2-ERK1/2 pathway and
the PI3K/Akt pathway in AML cells has not been investigated to date. Our results
demonstrate that AML cells are sensitive to the inhibition of either the MEK1/2-ERK1/2
pathway or the PI3K/Akt pathway with no additive or synergistic effect for the
simultaneous inhibition of both pathways.
In addition to its cytotoxic effect on a majority of AML cell lines, we have shown that
LeTx also induces cell cycle arrest in a large subset of cell lines, independently of their
38
sensitivity to the cytotoxic effects of the LF-mediated inhibition of the MAPK pathway.
One of the four cell lines that did not show a cytotoxic response to LeTx, in addition to
four of the seven cell lines that did show a cytotoxic response had an increase in the
fraction of cells in the G0/G1 phase along with a decrease in the fraction of cells in the
G2/M and S phases in surviving cells at the highest concentration compared to controls.
We then determined the activity of the Ras-Raf-MEK1/2-ERK1/2 pathway in AML cell
lines by assessing phospho-ERK1/2 levels using single cell intracellular staining and
comparing it to the cytotoxic response of these cells to the LF-mediated inhibition of the
MAPK pathway. Cell lines in which the LF-mediated inhibition of the MAPK pathway
induced cytotoxicity were positive for phospho-ERK1/2 indicating an active Ras-Raf-
MEK1/2-ERK1/2 pathway while cell lines in which the inhibition of this pathway did not
induce cytotoxicity were negative for phospho-ERK1/2. This indicates that sensitivity of
AML cells to the LF-mediated inhibition of the MAPK pathway is determined by the
activity of the MAPK pathway and that phospho-ERK1/2 levels may be used as a marker
to predict sensitivity of AML cells to the inhibition of the MAPK pathway. Predicting a
cells response to the inhibition of a signaling pathway, such as the MAPK pathway, may
be more complicated than a simple determination of the activity of the pathway, however,
in the absence of alternatives, this remains the only available means of assessing the
importance of a particular pathway to the survival of cells.
Analysis of the mechanism of cell death in AML cell lines following LF-mediated
inhibition of the MAPK pathway revealed that LeTx induces caspase-independent, non-
apoptotic cell death in AML cells. Cells treated with LeTx for 24 h were positive for both
Annexin V and PI while being negative for the presence of active caspases. Anthrax
39
lethal toxin has been shown to induce caspase-dependent, apoptotic cell death in a
number of tumor types, including melanoma (Koo HM, 2002) However, LeTx-mediated
inhibition of the MAPK pathway has not been investigated in AML cells and the type of
cell death induced by the LF-mediated inhibition of this pathway may be dependent on
the tumor type. Furthermore, though some studies have shown that Ras inhibitors and
MEK inhibitors do induce apoptosis in AML cell lines, the non-apoptotic cell death
induced by LeTx in AML cells is not surprising knowing the different mechanism of
action of LeTx which catalytically cleaves all MEKs leading to the complete inhibition of
all branches of the MAPK pathway (James JA, 2003) (Milella M E. Z., 2002) (Morgan
MA, 2001).
In this study we have shown that a majority of AML cell lines are sensitive to the LF-
mediated inhibition of the MAPK pathway, hence confirming the potential for selectively
targeting this pathway in AML. Furthermore, we have demonstrated that LeTx-induced
cytotoxicity in AML cells, following inhibition of the MAPK pathway, is non-apoptotic
and is dependent on phospho-ERK1/2 levels in targeted cells.
40
Grant Support:
This work was supported in part by the Intramural Research Program of the National
Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.
41
Bibliography
Abi-Habib, R.J., Singh, R., Leppla, S.H., Greene, J.J., Ding, Y., Berghuis, B., …
Frankel, A.E. (2006). Systemic anthrax lethal toxin therapy produces regressions
of subcutaneous human melanoma tumors in athymic nude mice. Clin Cancer
Res, 2, 7437-43.
Abi-Habib, R.J., Urieto, J.O., Liu, S.H., Leppla, S.H., Duesbery, N.S., & Frankel, A.E.
(2005). Braf status and mitogen-activated protein/extracellular signal-regulated
kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal
toxin. Mol Cancer Ther, 4(9),1303-10.
Abrami, L., Liu, S., Cosson, P., Leppla, S.H., & Van der Goot, F.G. (2003). Anthrax
toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin
dependent process. J Cell Biol, 160(3), 321–8.
Abrami, L., Leppla, S.H., & Van der Goot, F.G. (2006). Receptor palmitoylation and
ubiquitination regulate anthrax toxin endocytosis. J Cell Biol, 172(2), 309-20.
American Cancer Society. (2013). Cancer facts & figures. Atlanta: American Cancer
Society, Inc.
American Cancer Society. (2013, January 18). Learn about cancer. Retrieved from
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-
acute-myeloid-myelogenous-classified
Dhillon, A.S., Hagan, S., Rath, O., & Kolch, W. (2007). MAP kinase signalling pathways
in cancer. Oncogene, 26(22), 3279-3290.
Bennett, J.M., Kouides, P.A., & Forman, S.J. (2002). The myelodysplastic syndromes:
Morphology, risk assessment, and clinical management. Int J Hematol., 2, 228-
238.
Bradley, K.A., Mogridge, J., Mourez, M., Collier, R.J., & Young, J.A. (2001).
Identification of the cellular receptor for anthrax toxin. Nature, 414(6860), 225-9.
Chopra, A.P., Boone, S.A., Liang, X., & Duesbery, N.S. (2003). Anthrax lethal factor
proteolysis and inactivation of MAPK kinase. J Biol Chem, 278(11), 9402-6.
Davies, S.P., Reddy, H., Caivano, M., & Cohen, P. (1999). Specificity and mechanism of
action of some commonly used protein kinase inhibitors. Curr Opin Chem Biol.,
351(Pt 1), 95-105.
Deuquet, J., Lausch, E., Superti-Furga, A., & Van der Goot, F.G. (2012). The dark sides
of capillary morphogenesis gene 2. The EMBO Journal, 31(1), 3-13.
42
Duesbery, N.S., Webb, C.P., Leppla, S.H., Gordon, V.M., & Klimpel, K.R., Copeland
T.D., … Vande Woude, G.F. (1998). Proteolytic inactivation of MAP-kinase-
kinase by anthrax lethal factor. Science, 280(5364), 734-7.
Gedaly, R., Angulo, P., Hundley, J., Daily, M.F., Chen, C., & Evers, B.M. (2012). PKI-
587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways
synergistically inhibit HCC cell proliferation. J Surg Res, 176(2), 542-8.
Haagensen, E.J., Kyle, S., Beale, G.S., Maxwell, R.J., & Newell, D.R. (2012). The
synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR
inhibition. Br J Cancer, 106(8), 1386-94.
Hilger, R.A., Scheulen, M.E., & Strumberg, D. (2002). The Ras-Raf-MEK-ERK pathway
in the treatment of cancer. Onkologie, 25(6), 511–8.
James, J.A., Smith, M.A., Court, E.L., Yip, C., Ching, Y., Willson, C., & Smith, J.G.
(2003). An investigation of the effects of the MEK inhibitor U0126 on apoptosis
in acute leukemia. Hematol J, 4(6), 427-32.
Kim, S.H., Yoo, J.C., & Kim, T.S. (2009). Nargenicin enhances 1,25-dihydroxyvitamin
D(3)- and all-trans retinoic acid-induced leukemia cell differentiation via
PKCbetaI/MAPK pathways. Biochem Pharmacol., 77(11), 1694-701.
Konopleva, M., Contractor, R., Kurinna, S.M., Chen, W., Andreeff, M., & Ruvolo, P.P.
(2005). The novel triterpenoid CDDO-Me suppresses MAPK pathways and
promotes p38 activation in acute myeloid leukemia cells. Leukemia, 19(8), 1350-
4.
Koo, H.M., VanBrocklin, M., McWilliams, M.J., Leppla, S.H., Duesbery, N.S., & Vande
Woude, G.F. (2002). Apoptosis and melanogenesis in human melanoma cells
induced by anthrax lethal factor inactivation of mitogen-activated protein kinase
kinase. Proc Natl Acad Sci U S A, 99(5), 3052-7.
Lee, J.T Jr., & McCubrey, J.A. (2002). The Raf/MEK/ERK signal transduction cascade
as a target for chemotherapeutic intervention in leukemia. Leukemia, 16(4), 486–
507.
Liu, S., Bugge, T.H., & Leppla, S.H. (2001). Targeting of tumor cells by cell surface
urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem, 276(21),
17976-84.
Melnyk, P.A., & Collier, R.J. (2006). A loop network within the anthrax toxin pore
positions the phenylalanine clamp in an active conformation. Proc Natl Acad Sci
U S A, 103(26), 9802-7.
43
Milella, M., Estrov, Z., Kornblau, S.M., Carter, B.Z., Konopleva, M., Tari, A., …
Andreeff M. (2002). Synergistic induction of apoptosis by simultaneous
disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous
leukemia. Blood, 99(9), 3461-4.
Milella, M., Kornblau, S.M., Estrov, Z., Carter, B.Z., Lapillonne, H., Harris, D., … Andreeff M. (2001). Therapeutic targeting of the Mek/Mapk signal transduction
module in acute myeloid leukemia. The Journal of Clinical Investigation, 108(6),
851-9.
Moayeri, M., & Leppla, S.H. (2004). The roles of anthrax toxin in pathogenesis. Current
Opinions in Microbiology, 7(1), 19–24.
Morgan, M.A., Dolp, O., & Reuter, C.W. (2001). Cell-cycle-dependent activation of
mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines
and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.
Blood, 97(6), 1823-34.
Ramage, J., Vallera, D.A., Black, J., Aplan, P., Kees, U., & Frankel, A.E. (2003). The
diphtheria toxin/urokinase fusion protein (Dtat) is selectively toxic to Cd87
expressing leukemic cells. Leukemia Research, 27(1), 79-84.
Ramirez, D.M., Leppla, S.H., Schneerson, R., & Shiloach, J. (2002). Production,
recovery and immunogenicity of the protective antigen from a recombinant strain
of Bacillus anthracis. J Ind Microbiol Biotechnol, 28(4), 232-8.
Ricciardi, M.R., Scerpa, M.C., Bergamo, P., Ciuffreda, L., Petrucci, M.T., Chiaretti, S… Milella, M. (2012). Therapeutic potential of MEK inhibition in acute
myelogenous leukemia: Rationale for “vertical” and “lateral” combination
strategies. J Mol Med., 90(10), 1133-44.
Scobie, H.M., Rainey, J.A., Bradley, K.A., & Young, J.A. (2003). Human capillary
morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad
Sci U S A, 100(9), 5170–4.
Shimizu, T., Tolcher, A.W., Papadopoulos, K.P., Beeram, M., Rasco, D.W., Smith, L.S.,
… Patnaik, A. (2012). The clinical effect of the dual-targeting strategy involving
PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced
cancer. Clin Cancer Res, 18(8), 2316-25.
Singh, R., Cadeddu, R.P., Fröbel, J., Wilk, C.M., Bruns, I., Zerbini, L.F., … Czibere, A.
(2011). The non-steroidal anti-inflammatory drugs Sulindac sulfide and
Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia
cells through an AP-1 dependent pathway. Apoptosis, 16(9), 889-901.
44
Wee, S., Jagani, Z., Xiang, K.X., Loo, A., Dorsch, M., Yao, Y.M., … Stegmeier, F.
(2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS
mutant cancers. Cancer Res, 69(10), 4286-93.
Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D.,
… Marais, R. (2004). V599EB-Raf is an oncogene in melanocytes. Cancer Res,
64(7), 2338–42.
Williams, T.M., Flecha, A.R., Keller, P., Ram, A., Karnak, D., Galbán, S., … Sebolt-
Leopold, J. (2012). Cotargeting MAPK and PI3K signaling with concurrent
radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer
Ther, 11(5), 1193-202.
Wu, J., Wong, W.W., Khosravi, F., Minden, M.D., & Penn, L.Z. (2004). Blocking the
Raf/Mek/Erk pathway sensitizes acute myelogenous leukemia cells to lovastatin-
induced apoptosis. Cancer Res, 64(18), 6461-8.
Xiao, Y., Zou, P., Wang, J., Song, H., Zou, J., & Liu, L. (2012). Lower phosphorylation
of p38 MAPK blocks the oxidative stress-induced senescence in myeloid
leukemic CD34(+)CD38 (-) cells. J Huazhong Univ Sci Technolog Med Sci,
32(3), 328-33.
Zaidi, S.K., Dowdy, C.R., Van Wijnen, A.J., Lian, J.B., Raza, A., Stein, J.L., … Stein,
G.S. (2009). Altered runx1 subnuclear targeting enhances myeloid cell
proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK
Network. Cancer Research, 69(21), 8249-55.